



Consumer Healthcare Products Australia

Advancing Responsible Self-Care

Annual Report 2021-2022





CHP Australia Purpose & Mission

Our members are manufacturers and distributors of consumer healthcare products, which includes nonprescription medicines. CHP Australia also represents businesses that support the industry. These include advertising agencies and PR firms as well as legal, statistical and regulatory consultancy companies and individuals.

Purpose

Advance consumer health through responsible self-care.

Mission

To enhance the health and well-being of Australians through access to evidence-based healthcare products and solutions.

CHP Australia Strategic Goals 2021–2023

CHP Australia's 3 year strategic plan is structured around 4 key pillars for action:



- 6** Chair and CEO's Message
- 7** AdCheck Service - Launch of TVC classification
- VOICE OF INDUSTRY**
- 8** Setting the Industry Agenda
- 11** Leading on Issues Management
- REGULATORY ENVIRONMENT**
- 12** Driving Regulatory Reform
- PROMOTING GREATER SELF-CARE**
- 16** The Self-Care Opportunity
- 17** Health Literacy
- CHP AUSTRALIA**
- 18** Self-regulation
- 20** Board
- 22** Subcommittees and Working Groups
- 23** Your Support Team
- 24** Events
- 26** Contact Details

Chair and CEO's Message

Reflecting on another eventful year characterised by lockdowns, plagued by ongoing supply chain issues, and culminating in a shift in the political landscape, we are confident in saying that Consumer Healthcare Products Australia (CHP Australia) and its members have consistently risen to the occasion to meet these and other challenges.

Despite the continuing impact of, and new challenges arising from, the pandemic, we remained steadfastly committed to supporting better health outcomes for Australians and contributing to a healthier future through responsible self-care.

There were several significant achievements, most notably:

- The elevation of self-care and health literacy in national health policy through the National Preventive Health Strategy;
- A clearer, pragmatic and common sense revised Therapeutic Goods Advertising Code;
- A well-received conference on the evolving consumer healthcare journeys instore and online;
- Expanding our AdCheck advertising compliance service to include TVC classifications;
- Strengthening our engagement and relationship with the Department of Industry, including securing the Industry Minister's participation in our Annual Stakeholder Summit.
- Advancing medicines literacy in partnership with Life Education and Sydney North Health Network; and
- Expanding the evidence-base supporting self-care and health literacy through our Strategic Self-Care Research Program.

It was another landmark year for self-care policy in Australia and globally. Following strong advocacy by CHP Australia and our partners in self-care, the *National Preventive Health Strategy 2021-2030* (NPHS) influenced the status of self-care in national health policy. For the first time "promoting self-determination and self-care" were incorporated into the principles of a long-term national health policy. Additionally, our efforts helped secure the development of the National Health Literacy Strategy (currently underway), and the National Consumer Engagement Strategy, both essential enablers of self-care.

Seizing on this momentum, we established the Self-Care Subcommittee (SCSC) to guide and coordinate our efforts in advancing self-care. The SCSC developed the Strategic Self-Care Research Program and will oversee the execution of this initiative. Two research projects have been completed in the past year.

The consumer survey, *The Self-Care Opportunity*, provided unique insights into consumer self-care behaviour and was very well-received by local and international stakeholders. An audit of sources of self-care information in Australia confirmed a plethora of reliable resources. The findings of these projects will provide the foundation for further research to support

consumers and healthcare professionals to progress self-care.

On the international front, a joint collaboration between WHO and the Global Self-Care Federation (GSCF) resulted in the launch of the first phase of the Self-Care Readiness Index (SCRI), an innovative research and policy tool that examined the level of self-care in 10 countries based on key indicators. Australia has been included in the second phase of the SCRI, covering a further 10 countries identified by the WHO. The results will be launched in the second half of 2022.

Our AdCheck advertising service has experienced significant growth throughout its second year of operation. Increasing uptake and positive customer feedback has led to the expansion of the team of expert advisors, and the addition of TVC classifications to its comprehensive range of services.

CHP Australia has been a member of the Department of Industry's Supply Chain Roundtable and we have cemented our position as our industry's voice in the ongoing challenges the pandemic presents.

We would like to express our gratitude to the membership for their loyal support over the past year, and in particular for remaining fully engaged in committee activities – these are the lifeline of the organisation and are vital to ensure that we effectively represent the interests of the members and the industry.

We also thank the CHP Australia board for its guidance and support for the secretariat team. And finally, a word of sincere thanks to the secretariat team for their dedication and commitment.



Phil Lynch
Chair



Deon Schoombie
Chief Executive Officer



AdCheck Service- Launch of TVC classification


The last 2 years since AdCheck's launch has seen the service go from strength to strength. Feedback from users has been overwhelmingly positive. Based on user feedback, a new platform was implemented in 2022 to simplify the application process.

An exciting expansion of the service was launched at the end of 2021/22. We now provide full TVC broadcast compliance reviews including classifications. This is included in the fee for the TGAC review at no additional cost - providing even better value for AdCheck users!

For more information please visit adcheck.com.au

 **120+** companies using AdCheck

 **4000+** pieces of advertising reviewed since launch, including TV, radio, in-store, online, print

 Ran multiple training workshops to build industry expertise on the TGAC (Therapeutic Goods Advertising Code)

Digital & Social Media Guidelines

CHP Australia provides detailed guidelines to assist advertisers



Highlights of the AdCheck Service Include:

Experience – At CHP Australia we have over 25 years of experience performing detailed advertising compliance checks and are well known as the benchmark regulatory experts in Australia for therapeutic goods. Our AdCheck team has in-depth expertise on the intricacies of the Therapeutic Goods Act, Regulations and Advertising Code, which is arguably the most detailed, complex legislation for consumer goods. We stay up to date on any changes and as the industry body representing therapeutic goods we have strong relationships with the TGA and the Department of Health.

Support managing complaints – As a client of CHP Australia, if a complaint arises, we will professionally assist you as indicated in our Term and Conditions. Our expertise includes many years of dealing with complaints (CRP and CHP Australia complaints processes).

Coaching and compliance training – Our aim is to assist you to reach compliance on any given ad. We provide coaching and advice on how to reach compliance for an ad; we don't just provide an 'it needs fixing' response.

Unique AdCheck verification number – CHP Australia is well known and respected throughout industry for its expertise in compliance for therapeutic goods; a CHP Australia AdCheck number assigned to compliant ads represents quality and assurance and can be verified upon request.

More information can be found on our website: adcheck.com.au



Setting the industry agenda




THE ROLE OF SELF-CARE

Self-care, as a health policy and practice tool, is a comprehensive, evidence-based, and complementary component of health that encourages and empowers individuals to take greater personal responsibility for their health and well-being, contributing to better health outcomes and lower health service costs. CHP Australia has consistently advocated for self-care to be elevated in national health policy and we are pleased to see advancements in recent long-term health policy statements.

Self-care entails individuals taking greater personal interest in, and responsibility for, their health and well-being through practices including lifestyle, responsible use of medicines, diet and exercise. Increased consumer empowerment and access to medicines are key to greater self-care as shown in the Self-Care Pyramid.

OUR INDUSTRY'S ROLE IN SELF-CARE



ADVOCATING FOR INCREASED CONSUMER ACCESS AND BALANCED REGULATION

CHP Australia continued its advocacy in 2021/2022 for greater consumer access to nonprescription medicines and for proportionate, risk-based, regulation.

We achieved our outcomes by working collaboratively with:



The past 12 months saw ongoing progress for medicines access in relation to switch, Appendix M and S3 advertising.

This year, we continued to focus on manufacturing and sustainability issues by engaging with stakeholders, and keeping members informed, in relation to:

- Advanced Manufacturing Commercialisation Fund
- Austrade's Export Market Development Grants
- Chinese requirements for certification from a "competent authority"
- COVID pain points
- COVID Winter Preparedness
- Critical Infrastructure Reforms
- DISER's Supply Chain Roundtable (SCRT)
- Environmental impacts of medicines
- Export certificates
- Flood impacts
- Good Supplier Practice
- Government co-funding opportunities
- GMP/Technical Agreements
- Modern Manufacturing Initiative
- National Packaging Covenant
- National Plan to Transition Australia's National COVID-19 Response
- Office of Supply Chain Resilience (OSCR) – follow-up on critical plastics
- PIC/S updates and adoption
- Product Stewardship Initiatives
- Productivity Commission's supply chain review
- RAT procurement plans
- Roundtable on critical plastics
- Senate inquiry into manufacturing
- Simplified Trade System – Project for Streamlining the Cargo intervention Model
- Skills Priority List
- Supply Chain Resilience Initiative
- TGA's Medicine Shortages Working Party (MSWP) and Medicines Shortages Section

Leading on Issues Management

CHP Australia is the voice of the nonprescription medicines industry with external stakeholders and in the media. CHP Australia advocates for issues important to the industry, promotes the economic and social value of the industry, protects the sector's reputation, and supports consumer education about the responsible use of nonprescription medicines and self-care.

CHP Australia has continued to build on our advocacy efforts - accommodating shifting policy priorities and adjusting to changes in the political landscape - to ensure members concerns and issues are being heard in all appropriate forums.

By working collaboratively with stakeholders and advocacy partners, and closely monitoring the political environment, CHP Australia continues to achieve outcomes important to members. Most notably:

- Secured bi-partisan support for a range of our industry's election priorities.
- Further strengthened our engagement and relationship with the Department of Industry, including securing the Industry Minister's participation in our annual Stakeholder Summit.
- Secured the priority development of the National Health Literacy Strategy, and National Consumer Engagement Strategy.
- Significantly elevated the role of self-care in the final National Preventive Health Strategy.
- Led efforts with government and industry stakeholders to address intentional analgesics misuse.

- Ensured specific skills vulnerabilities/shortages affecting the industry were among the handful identified in the Skills Priority List as requiring priority policy attention.
- Contributed non-regulatory insights and feedback to nine different Government Departments, Committees and advisory bodies via 11 submissions.
- Provided important industry-specific insights quoted in the final report of the Senate Inquiry into the Australian Manufacturing Industry.
- Established productive relationships with a broader range of non-political stakeholders and government agencies.

CHP Australia remains at the forefront of media engagement and emerging issues management, providing media surveillance and analysis on key industry, product and ingredients issues across the Australian and international media. We also continued to lead the way on communicating the value of self-care to stakeholders through thoughtful media engagement.

CHP Australia continued to contribute to and promote insightful global and local research, including research that demonstrates the economic, social and health benefits of consumer empowerment in health and the opportunities available through greater self-care.



Driving Regulatory Reform

CHP Australia continued to influence outcomes at a time of unprecedented regulatory reform. Our work with members, the TGA and other stakeholders drives outcomes that are practical, proportionate, effective and implemented within realistic timeframes.

In the 12 months since July 2021, we considered 51 regulatory consultations and made submissions in relation to 38. Through our Teams, Working Groups and Subcommittees we discussed reforms and issues with members and agreed on industry positions. Through hundreds of interactions with individual members we explored regulatory complexities and provided support and advice to members.

This close collaboration between the Secretariat, the Members and other stakeholders is what drives our advocacy.



Medicines and Medical Devices Regulation (MMDR) Review

The roll-out of the MMDR reforms continued during the past year. CHP Australia kept working with the TGA, members and other stakeholders to support, interpret and refine the ongoing reforms. Some of the notable examples for listed medicines, complementary medicines and medical devices include:

- De-duplication of the Permissible Ingredients Determination (vs the Poisons Std, TGO 92 and TGO 95)
- Evidence requirements for listed medicines (including sunscreens)
- Mandatory data requirements for listed ingredients
- Use of reports from Comparable Overseas Bodies to support applications
- Permissible ingredients processes
- Data protection for the Listed Assessed pathway
- Market exclusivity for new listed ingredients
- Pharmacovigilance



Advertising

Therapeutic goods advertising continues to be a major concern for members. Throughout the reforms our advocacy has involved participation in the TGA consultations (public and targeted), advice to members, member workshops, meetings with the TGA, meetings with other stakeholders and the socialisation of CHP Australia positions. In particular, our membership of the Therapeutic Goods Advertising Consultative Committee (TGACC) has allowed us to influence discussions and to obtain valuable insights for our members. Key achievements from the past 12 months include:

- Publication of a simpler and clearer Therapeutic Goods Advertising Code (as advocated for by CHP Australia)
- TGA adoption of suggested transition arrangements
- Successful advocacy to permit references to COVID testing in advertising
- Updates to CHP Australia's Digital and Social Media Guidelines
- Expansion of the AdCheck service to include TVC classification
- Assisting members navigate the new TGAC and the new advertising guidelines (especially in relation to sampling, testimonials and endorsements)

- Assisting members with the TGA's complaints processes and sanctions regime
- Ongoing monitoring of advertising issues



TGA's Digital Transformation Program

Through collaboration, feedback and participation, we ensured that the consumer healthcare perspective is being properly incorporated into the TGA's Digital Transformation Project. Key activities included:

- Advancing member's interests
- Receiving regular updates from the TGA and providing to members
- Inclusion as a standing agenda item at Liaison meetings
- Collecting issues to be addressed
- Secretariat and Member feedback to TGA
- Secretariat and member participation on TGA pilots and working groups
- Participation in Beta testing (e.g. new ARTG Search function)





Medical Device Reforms

Throughout the year, we continued to explore opportunities to grow and develop our expertise in relation to medical devices. Key activities included:

- Membership of, and active participation at, the TGA's RegTech Forum
- Establishing CHP Australia's Devices Team
- Close examination of the Medicines/ Devices interface
- Developing transition arrangements for reclassification
- Investigating reforms to the Medical Device Framework which differ from EU MDR
- Making submissions in relation to consultations (both public and targeted)
- Publicising and attending webinars and seminars
- Assessing indirect impacts on other lower risk products
- Review of, and input into, new TGA guidelines for medical devices




Scheduling and Scheduling Environment

Throughout the year we continued to assist members and collaborate with stakeholders to facilitate successful switch applications. We also worked with stakeholders to address obstacles to Appendix M implementation. Key activities included:

- Assisting members in navigating the processes and transition arrangements

- Advocating for members' positions in scheduling consultations and reforms
- NSW Poisons Advisory Committee membership
- Liaising with TGA and pharmacist organisations in relation to Appendix M
- Liaising with members and with the States and Territories regarding scheduling transitional arrangements
- Submissions to ACMS in support of members, down-scheduling and scheduling principles, including identifying significant unintended consequences of proposals
- Monitoring of the NZ classification environment with submissions as appropriate



Others

We also provided advocacy and member assistance to drive meaningful change across a wide range of other regulatory areas and issues, some of which included:

- Analgesic purchase limits
- APCO reforms (implementation of National Packaging Targets)
- Benzene in sunscreens
- Calcium and CV risk
- CBD reforms
- Fish Oil and atrial fibrillation
- Fluoride classification in New Zealand
- Foods for special medical purposes
- Greenwashing
- GSCF Environmental Sustainability Pledge
- Hand sanitisers – proposed amendments to the Poisons Standard
- Immunological responses to analgesics

- Liver toxicity of herbal substances
- Medicinal Cannabis reforms (e.g GMP, Labelling and Packaging)
- Microplastics
- Modern Slavery
- National Medicines Policy Review
- New Zealand legislative reforms
- Nicotine re-scheduling and E-cigarettes
- Nitrosamines
- NSW Health legislative changes
- Omega 3s
- Paracetamol Review
- Paracetamol overdose
- Paracetamol and blood pressure
- Pholcodine (classification in New Zealand)
- Pholcodine (international reviews)
- Probiotics and pregnancy
- Proprietary Ingredient issues
- Sports supplements
- Sunscreen Standard (update, adoption, transition)
- Sunscreen (Product Safety Standard Bill) in New Zealand
- Sunscreens' impact on marine environments
- Testimonials and Endorsements in advertising
- ECHA Titanium Dioxide restriction implications
- US FDA Final Order for Sunscreens
- TGA Review – Efficacy of Aerosol Sunscreens
- TGA Review – Safety of Octocrylene



The Self-Care Opportunity

Self-Care is a complementary, evidence-based approach that empowers and supports individuals to take their health and well-being into their own hands. It can also help governments foster a more resilient and self-sufficient health population. It encompasses the knowledge, skills and activities individuals can utilise every day to enhance their health and well-being, support better health decision-making, appropriately self-manage illness and disease, and responsibly use medicines and other healthcare resources. We will continue to advocate for self-care to be embedded in Australia's National Health Policy and continue to build the evidence base for policy development. In addition, we support the Australian Self-Care Alliance whose Self-Care Policy Blueprint outlines key strategies for furthering the development of sound policies.

Health literacy is a vital enabler of greater self-care. This includes not only the ability to find and understand information and services, but the skills to interpret health information and appropriately apply it to individual circumstance.

To further build the evidence base for self-care, CHP Australia conducted a survey of 2000 adults to uncover Australians' knowledge and skills in managing everyday health conditions, including motivations to take greater care of themselves, levels of health literacy, use of digital health technologies, and interactions with healthcare professionals.

Overwhelmingly Australians (97%) feel responsible for managing their own health and a significant proportion (84%) want to improve their health skills and knowledge. But the findings show close to one in three (30%)

consider their health literacy level is low, presenting a substantial barrier to improving community wellness and health outcomes. The Report also uncovered more than half of Australians find it difficult to identify credible sources online. Nearly one-third (28%) would trust the information they find online more if it was independently verified as credible.

The Self Care Opportunity Report

clearly shows an urgent need to help Australians with digital health literacy - to know where to find, how to interpret, and how to use health information from online sources. This is very important as we can clearly see those with higher literacy levels have higher engagement in their health.

Some additional findings:

- Australian's health literacy levels are mixed, with just one in five (22%) rating their health literacy as high, one in three (30%) believe their health literacy is low.
- Eight out of ten Australians (81%) use health websites, apps, or social media to manage common health conditions, including online health bookings to telehealth consultations.
- One quarter (24%) monitor their health with phone apps and health trackers, and one in five (19%) use a smartwatch.
- Millennials lead the digital charge with 80% going online for healthcare information before seeing a GP or pharmacist. One in two Baby Boomers (47%) go online as a first



port of call.

- Nine in ten Australians want parents and schools to do more to teach children health literacy.
- Health care professionals also play a trusted role with 89% somewhat likely to seek advice from GPs and four in five (82%) a pharmacist for short-term health conditions.
- Three-quarters of Australians (73%) rely on pharmacists for advice on using prescription medicines and three in five (58%) on non-prescription medicines.

We will continue to advocate for Self-Care to be embedded in Australia's National Health Policy and continue to build the evidence base for policy development. In addition we support the Australian Self-Care Alliance whose Self-Care Policy Blueprint outlines key strategies for furthering the development of sound policies.



Australian Self-Care Alliance - CHP Australia spearheaded the establishment of the Self-Care Alliance in 2014 at Parliament House, Canberra, bringing together stakeholders with an interest in advancing self-care

Health Literacy

The most critical enabler of responsible self-care is health literacy. An Australian Bureau of Statistics (ABS) 2006 study showed that only 40% of Australians had satisfactory health literacy levels.



In 2021/2022, CHP Australia continued our partnership with Life Education Australia to promote self-care and boost health literacy among Australian parents and teachers. We funded the update of the 'Mind your Medicines' curriculum module including the development of new audio/visual and digital assets.



We had a very successful collaboration with the Sydney North Health Network (SNHN) this past year, including sponsorship of their GPs in High Schools program. With a goal of building health literacy, CHP Australia provided content on responsible medicines usage to years 11 and 12 students, as well as general self-care tips. We look forward to continuing this program in 2022/2023 as well as sponsoring the Preventive Health Symposium in September 2022.



It was another productive year for our world body, the Global Self-Care Federation (GSCF). CHP Australia and GSCF share the same key strategic goals - advancing responsible self-care and raising health literacy as a key driver of self-care.

The two pillars of GSCF's strategic plan are: (1) embed self-care as a key pillar of global health systems, and (2) be the trusted global partner, promoting the value and benefits of self-care for its members and healthcare stakeholders, in particular WHO.

As a member of the GSCF board CHP Australia has been actively involved in the intensive work program of the GSCF. Our CEO chaired the Self-Care Literacy Working Group responsible for the development of the Self-Care Literacy White Paper. He also co-chaired the Economic & Social Value of Self-Care Working Group which oversaw a major research project that investigated the value of self-care for populations at a global level.

Recognising the importance of health literacy as a critical enabler of self-care, GSCF partnered with the Global Health Literacy Academy to develop a white paper to promote self-care literacy as a health priority. This initiative supports the *WHO Health 2020* strategy that identified health literacy as a key element in promoting consumer and community empowerment and participation in health. The white paper, which identified self-care literacy as a subset of health literacy, was launch via an international webinar in April 2022 and was well-received by stakeholders.

The landmark research study, *The Global Social and Economic Value of Self-Care*, aimed to distinguish self-care as a key contributor to the health of individuals and healthcare systems worldwide. It is the first research project that analysed the worldwide value of self-care and also the first study that included data from low and middle-income countries, giving a truly global value of self-care.

The Self-Care Readiness Index (SCRI) is an advocacy-centred research initiative and the outcome of a collaboration with WHO to establish self-care as a global health priority. At its core the SCRI is an advocacy tool to initiate conversations and to serve as a catalyst for further debate with stakeholders in the health arena. The ultimate goal is to develop a comprehensive and coordinated global advocacy drive.

The SCRI identifies four enablers or "measures" in relation to self-care with which to anchor discussions. These are: stakeholder support and adoption, consumer and patient empowerment, self-care health policy and the regulatory environment.

Phase 1 of the research reported on 10 countries identified in collaboration with WHO and was launched in September 2021. Australia is included in Phase 2 of the study and the results will be launched in the second half of 2022.

Self-care offers numerous benefits that extend from the individual to the whole community. Self-care health data has the potential to improve health outcomes, contributing to improved public health for the entire population.

The current legal, policy and regulatory environment is not conducive to harnessing the full potential of self-care health data: legal and regulatory frameworks are lagging behind innovation while existing self-care health data is fragmented and of varying quality.

GSCF advocates for changes in the policy environment for self-care health data that will enable individuals and society to harness all its benefits. In particular, GSCF calls for action in the following areas: adopting fit-for-purpose regulatory frameworks, standardising self-care data and building an inclusive and trustworthy digital self-care environment.

Self-regulation

CHP Australia has consistently supported a full range of regulatory and non-regulatory approaches to the control of therapeutic goods. In our view, the ideal set of controls includes judicious use of self-regulatory, co-regulatory and non-regulatory approaches consistent with the COAG Principles of Best Practice Regulation.

Complaints Panel Determinations

There was one complaint this year in relation to the Little Coughs range of products which involved two separate Panel hearings and two separate Appeal determinations. The full determinations are published on the CHP Australia website, but can be summarised as follows:

Little Coughs (Hearing #1)

- In October 2021, the Panel considered a complaint from iNova Pharmaceuticals Pty Ltd (“iNova”) about the promotion by Care Pharmaceuticals Pty Ltd (“Care”) of their Little Coughs Ivy Leaf (Hedera helix) (“Little Coughs”) range of products for use in children under 2 years of age.
- iNova complained that Care had breached sections 4.1 and 5.1.4 of the Code of Practice (“the Code”) because there was insufficient supporting evidence to justify the administration of the Little Coughs products to children in the 6 months to 2 years age group.
- Care contended that Hedera helix could safely be provided to the 6 months to 2 year patient population, but refused to provide the supporting data to iNova (citing, among other things, the confidential and proprietary nature of the data).
- The Panel considered that Section 5.1.4 of the Code required members to provide substantiation for claims

without delay upon request, even if that substantiation was based on confidential, proprietary information.

- The Panel found Care to be in breach of section 5.1.4 of the Code in failing to comply with iNova’s request for the substantiation.
- The Panel directed Care to provide to iNova the evidence held by Care to support the safety of the Little Coughs products for children in the 6 months to 2 years age group.
- The Panel deferred its consideration whether section 4.1 had been breached pending the provision by Care of its supporting data.

Little Coughs (Appeal #1)

- In November 2021, the Arbitrator considered an appeal by Care challenging the Panel’s findings in relation to section 5.1.4.
- The Arbitrator dismissed the appeal and confirmed the Panel’s direction to Care to provide iNova with the evidence held by Care to support the use of the Little Coughs products for children in the 6 months to 2 years age group.

Little Coughs (Hearing #2)

- In December 2021, Care provided to iNova, with a copy to CHP Australia, a list of 47 references on which it relied to support its claims, together with submissions.
- In February 2022, the Panel considered a complaint from iNova that the supplied references did not support the claims made by Care.
- The Panel found that the references provided by Care did not support the efficacy and safety of the Little Coughs products for children in the

6 months to 2 years age range. The Panel concluded that, in promoting those products for use in children in that age group, Care had engaged in unconscionable commercial practice, in breach of Section 4.1 of the Code.

- The Panel determined that, having regard to the safety implications for children under 2 years of age, the breach was a severe breach.
- The Panel endorsed the following sanctions:
 - Care to pay a fine of \$25,000 for the breach of section 5.1.4
 - Care to pay a fine of \$25,000 for the breach of section 4.1
 - Care to immediately discontinue making the claims that its Little Coughs products can be used by children between the age of 6 months and 2 years
 - Care to immediately cease distribution from its premises of Little Coughs products bearing labels representing that they can be used by children between the age of 6 months and 2 years

Little Coughs (Appeal #2)

- In April 2022, the Arbitrator considered an appeal by Care which raised a number of objections to the Panel’s December 2021 Determination.
- The Arbitrator dismissed the appeal and confirmed the sanctions imposed by the Panel.



CHP Australia Board



Dr. Aniss Chami
Vitex



Jonathan Biddle
Care Pharmaceuticals (Treasurer)
(ceased 30/06/2022)



Alison Holland
Aspen



Andrew Jenkin
iNova Pharmaceuticals
(Vice-Chair)



Phil Lynch
Chair



Jonas Marques
Bayer
(from 18/11/2021)



Alan Oppenheim
Ego Pharmaceuticals



Anish Patel
Haleon



David Rankine
Reckitt



Nadia Yu
J & J Consumer
(from 18/11/2021)

CHP Australia Board Composition

The CHP AUSTRALIA Board composition, nomination, elections and executive roles are all governed by the CHP AUSTRALIA Constitution.

The CHP AUSTRALIA Board consists of up to ten Directors as follows:

- Up to six Directors elected from the Official Delegates of the CHP AUSTRALIA Ordinary Members (Elected Directors)
- Up to four Directors appointed by the Board (Skills-based Directors)

The Elected Directors each hold office for two years and every year three of the Elected Directors retire from the Board. In advance of each annual retirement, CHP AUSTRALIA

calls for expressions of interest and holds elections for the three Director positions to be vacated. This ensures that there are opportunities for new Directors while maintaining continuity of expertise.

While each Elected Director must be the Official Delegate of an Ordinary Member, the Skills-based Directors can be drawn from a much wider set of candidates (including, for example, Honorary Life Members, Associate Members and non-members).

The CHP AUSTRALIA Elected Directors as at 30 June 2022:

- **Aniss Chami**, Vitex Pharmaceuticals
- **Alison Holland**, Aspen Pharmacare

- **Andrew Jenkin**, iNova Pharmaceuticals (Vice Chair)
- **Alan Oppenheim**, Ego Pharmaceuticals
- **Anish Patel**, Haleon

- **Nadia Yu**, Johnson & Johnson Consumer Health

The CHP AUSTRALIA Skills-based Directors as at 30 June 2022:

- **Phil Lynch** (Chair)
- **Jonas Marques**, Bayer Australia
- **David Rankine**, Reckitt

CHP Australia Members

Ordinary Members (at time of printing)



Associate Members (at time of printing)



Subcommittees and Working Groups


CHP Australia subcommittees and working groups provide you with the opportunity to be directly involved with CHP Australia’s work programme and help deliver our strategic plan. Members of these groups meet regularly to plan activities and guide how we shape the regulatory environment, advocate on key issues and provide member services and engagement.

This gives members the opportunity to:

- Contribute to the CHP Australia position on key issues
- Shape industry work
- Keep up to date with current issues
- Meet with the TGA

We greatly value the involvement of our subcommittees and working group members and would like to thank all members who give their time to achieve our shared goals.

For more information on how to get involved email us at info@chpaustralia.com.au



CHP Australia – Your Support Team

CHP AUSTRALIA SECRETARIAT



ADCHECK SERVICE



WE'RE HERE TO HELP

General Enquiries:
Suite 1, Level 2
35 Chandos St
St Leonards NSW 2065
Ph: +61 2 9922 5111
info@chpaustralia.com.au

AdCheck Enquiries:
Ph: +61 2 9922 5111
adcheck@chpaustralia.com.au

CHP Australia Events

Webinars

- 21 July 2021** Health & Nutritional Marketing Trends with 6AM Agency
- 8 September 2021** Data Analytics 101 with BCS Technology
- 7 October 2021** How to win at Social with Red Havas
- 10 March 2022** Code Update (TGAC) with TGA & AdCheck
- 4 May 2022** Search Engine Optimisation with Vine Digital
- 16 June 2022** Driving effectiveness in Marketing with 6AM Agency

TGAC Workshop

- Virtual TGAC Workshop** 11, 18 & 25 August 2021
- Virtual TGAC Workshop** 13, 20 & 27 October 2021
- Virtual TGAC Workshop** 9, 16 & 23 February 2022
- TGAC Workshop F2F** 23 March 2022
- Virtual TGAC Workshop** 13, 20 & 27 April 2022
- Virtual TGAC Workshop** 15, 22 & 29 June 2022

AGM

18 November 2021

DIAMOND AWARDS

18 November 2021

Conference

18 November 2021

Online purchasing behaviour & evolving digital landscape with Google

Retailing in post COVID: Purchasing behaviour & evolving landscape with Woolworths and HealthyLife

Consumer Healthcare Medical devices with MPT Innovation Group & MARCS Institute, Western Sydney University

Software Apps and Self Care – Utility, performance, and the role of regulation & Update on key TGA activities with Adjunct Prof John Skerritt


Retailing in post COVID: Purchasing behaviour & evolving landscape with the Pharmacy Guild of Australia

Member Forum

18 May 2022

Consumer Health Pharmacy Landscape with IQVIA

Maximise your Voice on LinkedIn with Red Havas



CHP Australia Member Services



Advice and Support

- Pool of expertise to utilise
- Confidential advice on regulatory, technical, marketing and media management issues
- Member workshops to navigate current/ pending regulatory reforms



Advocacy and Representation

- “Voice of industry” on issues impacting industry, segments, ingredients
- Member conduit to media, stakeholders, government, TGA
- Parliamentary Events
- Strength in numbers



Shaping Industry Initiatives

- Committee, working group involvement
- Share experiences with other members
- Contribute to the CHP Australia position/ shape industry work



Staying informed

- Keep up to date on issues
- Local and international monitoring of issues with briefs and alerts to members
- E-newsletters, alerts, events, seminars, workshops, web portal



Self Regulation

- CHP Australia Code
- CHP Australia Complaints Panel



Member Events

- World Class Industry Events
- Education Seminars
- Members Forums
- CHP Australia Diamond Awards for Excellence in Marketing & Sales



Member Training

- In house training and inductions
- Therapeutic Goods Advertising Training
- Member workshops

GENERAL ENQUIRIES

Suite 1, Level 2
35 Chandos St,
St Leonards NSW 2065

Ph: +61 2 9922 5111

info@chpaustralia.com.au
www.chpaustralia.com.au
ABN 55 082 798 952

MEMBERSHIP ENQUIRIES

Membership Services Manager
CHP Australia

Ph: +61 2 9059 2439

ADCHECK ENQUIRIES

Ph: +61 2 9922 5111
adcheck@chpaustralia.com.au

MEDIA ENQUIRIES

Public Affairs Manager

Ph: +61 2 9059 2442
media@chpaustralia.com.au



**Consumer Healthcare
Products Australia**

chpaustralia.com.au